1. SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

2. Trial profile Numbers lost to follow-up relate to those without information to the end of the scheduled treatment period for mortality (as well as morbidity) and for morbidity alone
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

3. Compliance with study simvastatin (>80% taken) at scheduled follow-up visits
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

4. Reasons for stopping study simvastatin tablets before scheduled end of study
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

5. Mean differences in plasma concentrations of lipids during follow-up, by allocated treatment
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

6. Effects of simvastatin dose allocation on first major vascular event
Analyses are of the numbers of participants having a first event of each type during follow-up (with non-fatal and fatal events considered separately), so there is some non-additivity between diff erent types of event. Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. The dashed vertical line shows the overall risk ratio. MI=myocardial infarction. CHD=coronary heart disease.
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

7. Effects of simvastatin dose allocation on first major vascular event by year of follow-up
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. The dashed vertical line shows the overall risk ratio. Analyses are of numbers of participants having a fi rst event during each year of follow-up and of those still at risk of a first event at the start of each year.
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

8. Effects of simvastatin dose allocation on first major vascular event in different categories of participant
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs.The dashed vertical line shows the overall risk ratio. p values of χ2 tests are given for heterogeneity between RRs within dichotomous categories and for trend within other categories (except for previous disease categories since there is some overlap between them). Lipid categories relate to measured values at the randomisation visit after all participants had been taking 20 mg simvastatin daily for 2 months during the run-in. MI=myocardial infarction. CHD=coronary heart disease. GFR (MDRD)=glomerular filtration rate estimated with modification of diet in renal disease equation.
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

9. Effects of simvastatin dose allocation on cause-specific mortality
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. The dashed vertical line shows the overall risk ratio. MI=myocardial infarction. CHD=coronary heart disease.
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

10. Effect of simvastatin dose allocation on site-specific cancer incidence
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. The dashed vertical line shows the overall risk ratio. Analyses are of the numbers of participants developing cancer at each site (excluding recurrences or new cancers at the same site), so there is some non-additivity between cancers at diff erent sites. Connective tissue includes breast, melanoma, skin, and other connective tissue cancers, but not non-melanoma skin cancer (which was prospectively to be considered separately).
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

11. Myopathy and raised alanine aminotransferase and creatine kinase concentrations
SEARCH Collaborative Group. Lancet 2010;epub 9 Nov